{"id":67802,"date":"2026-06-09T23:15:46","date_gmt":"2026-06-09T15:15:46","guid":{"rendered":"https:\/\/flcube.com\/?p=67802"},"modified":"2026-06-09T23:15:48","modified_gmt":"2026-06-09T15:15:48","slug":"sichuan-biokin-receives-fda-go-ahead-for-phase-iii-trial-of-dll3-targeting-adc-bl-m14d1-in-first-line-extensive-stage-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67802","title":{"rendered":"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Sichuan Biokin Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688506:SHA\">SHA: 688506<\/a>) announced today that the <strong>U.S. Food and Drug Administration (FDA)<\/strong> has granted clearance to proceed with a <strong>Phase III clinical study<\/strong> evaluating its antibody-drug conjugate (ADC) <strong>BL-M14D1<\/strong> in combination with immunotherapy for the <strong>first-line treatment<\/strong> of patients with <strong>extensive-stage small cell lung cancer (ES-SCLC)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Candidate<\/strong><\/td><td>BL-M14D1<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506)<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Phase III trial go-ahead<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line extensive-stage small cell lung cancer (ES-SCLC)<\/td><\/tr><tr><td><strong>Combination Therapy<\/strong><\/td><td>BL-M14D1 + immunotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-technology-platform\" class=\"wp-block-heading\">Drug Profile &amp; Technology Platform<\/h2>\n\n\n\n<h3 id=\"h-dll3-targeting-innovation\" class=\"wp-block-heading\">DLL3-Targeting Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target<\/strong>: Delta-like ligand 3 (DLL3), highly expressed in small cell lung cancer<\/li>\n\n\n\n<li><strong>Therapeutic Class<\/strong>: Antibody-drug conjugate (ADC)<\/li>\n\n\n\n<li><strong>Technology Platform<\/strong>: Shares same small-molecule technology platform as Biokin&#8217;s iza-bren<\/li>\n\n\n\n<li><strong>Differentiation<\/strong>: Novel approach targeting DLL3 in first-line ES-SCLC setting<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-data-foundation\" class=\"wp-block-heading\">Clinical Data Foundation<\/h2>\n\n\n\n<h3 id=\"h-second-line-es-sclc-results\" class=\"wp-block-heading\">Second-Line ES-SCLC Results<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Median Progression-Free Survival (mPFS)<\/strong><\/td><td>8.1 months<\/td><\/tr><tr><td><strong>Overall Response Rate (ORR)<\/strong><\/td><td>78.6%<\/td><\/tr><tr><td><strong>Confirmed ORR (cORR)<\/strong><\/td><td>71.4%<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Second-line ES-SCLC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 id=\"h-phase-iii-trial-design\" class=\"wp-block-heading\">Phase III Trial Design<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Setting<\/strong>: First-line extensive-stage small cell lung cancer<\/li>\n\n\n\n<li><strong>Regimen<\/strong>: BL-M14D1 in combination with immunotherapy<\/li>\n\n\n\n<li><strong>Strategic Rationale<\/strong>: Building on strong second-line efficacy data to address larger first-line patient population<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context-amp-market-opportunity\" class=\"wp-block-heading\">Disease Context &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ES-SCLC Burden<\/strong>: Represents approximately 70% of all small cell lung cancer cases at diagnosis<\/li>\n\n\n\n<li><strong>Treatment Gap<\/strong>: Limited effective options beyond platinum-etoposide chemotherapy plus immunotherapy<\/li>\n\n\n\n<li><strong>DLL3 Target Validation<\/strong>: Emerging target with strong biological rationale in SCLC<\/li>\n\n\n\n<li><strong>ADC Market Potential<\/strong>: Significant commercial opportunity in high-unmet-need indication with poor prognosis<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Development<\/strong>: FDA clearance enables international clinical development and potential global regulatory filings<\/li>\n\n\n\n<li><strong>Platform Validation<\/strong>: Success would validate Biokin&#8217;s small-molecule ADC technology platform<\/li>\n\n\n\n<li><strong>Commercial Positioning<\/strong>: Potential to establish BL-M14D1 as standard of care in first-line ES-SCLC<\/li>\n\n\n\n<li><strong>Pipeline Enhancement<\/strong>: Strengthens Biokin&#8217;s oncology portfolio alongside iza-bren<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-forward-looking-statements\" class=\"wp-block-heading\">Forward-Looking Statements<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward-looking statements regarding clinical development, regulatory pathways, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and execution challenges in international clinical development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260609_0BYQ.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688506_20260609_0BYQ.\"><\/object><a id=\"wp-block-file--media-e95bdd7c-424f-4ab8-9246-baed558a058a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260609_0BYQ.pdf\">688506_20260609_0BYQ<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/688506_20260609_0BYQ.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e95bdd7c-424f-4ab8-9246-baed558a058a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,151,62,857],"class_list":["post-67802","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-biokin-pharmaceutical","tag-clinical-trial-approval-initiation","tag-sha-688506"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase III clinical study evaluating its antibody-drug conjugate (ADC) BL-M14D1 in combination with immunotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67802\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer\" \/>\n<meta property=\"og:description\" content=\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase III clinical study evaluating its antibody-drug conjugate (ADC) BL-M14D1 in combination with immunotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67802\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-09T15:15:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-09T15:15:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67802#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67802\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer\",\"datePublished\":\"2026-06-09T15:15:46+00:00\",\"dateModified\":\"2026-06-09T15:15:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67802\"},\"wordCount\":360,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Biokin Pharmaceutical\",\"Clinical trial approval \\\/ initiation\",\"SHA: 688506\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67802#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67802\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67802\",\"name\":\"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-09T15:15:46+00:00\",\"dateModified\":\"2026-06-09T15:15:48+00:00\",\"description\":\"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase III clinical study evaluating its antibody-drug conjugate (ADC) BL-M14D1 in combination with immunotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67802#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67802\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67802#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - Insight, China&#039;s Pharmaceutical Industry","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase III clinical study evaluating its antibody-drug conjugate (ADC) BL-M14D1 in combination with immunotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67802","og_locale":"en_US","og_type":"article","og_title":"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer","og_description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase III clinical study evaluating its antibody-drug conjugate (ADC) BL-M14D1 in combination with immunotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).","og_url":"https:\/\/flcube.com\/?p=67802","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-09T15:15:46+00:00","article_modified_time":"2026-06-09T15:15:48+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67802#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67802"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer","datePublished":"2026-06-09T15:15:46+00:00","dateModified":"2026-06-09T15:15:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67802"},"wordCount":360,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Biokin Pharmaceutical","Clinical trial approval \/ initiation","SHA: 688506"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67802#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67802","url":"https:\/\/flcube.com\/?p=67802","name":"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-09T15:15:46+00:00","dateModified":"2026-06-09T15:15:48+00:00","description":"Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance to proceed with a Phase III clinical study evaluating its antibody-drug conjugate (ADC) BL-M14D1 in combination with immunotherapy for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67802#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67802"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67802#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Sichuan Biokin Receives FDA Go-Ahead for Phase III Trial of DLL3-Targeting ADC BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67802","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67802"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67802\/revisions"}],"predecessor-version":[{"id":67804,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67802\/revisions\/67804"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67802"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67802"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67802"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}